Prof. Dr. Kari Hemminki

Prof. Dr. Kari Hemminki

Prof. Dr. Kari Hemminki

Funktion:

Leiter

Telefonnr.:

0 62 21.42-18 00

Fax:

0 62 21.42-18 10

Gebäude:

TP 3

Raum:

B3.211

Werdegang

1973 PhD in Medizin, Universität Helsinki, Finnland
1973 MD in Medizin, Universität Helsinki, Finnland
1975 Docent in Biochemie, Universität Helsinki, Finnland
1976 - 1978 Postdoc in Molecular-Biologie, John Hopkins, Baltimore, USA

Forschungsgebiet

Diabetes, familiärer Krebs, Krebsgene

Ausgewählte Publikationen

Kharazmi E, Fallah M, sundquist K, Hemminki K. Familial risk of early and late onset cancer: nationwide prospective cohort study. BMJ 2012;345:e8076

Horn S, Figl A, Rachakonda SP, Fischer C, Sucker A, Gast A, Kadel S, Moll, I Nagore E, Hemminki K, Schadendorf D, Kumar R. TERT Promoter Mutations in Familial and Sporadic Melanoma. Science 2013;339(6122):959-61.

Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, Walker BA, Davies FE, Kaiser MF, Li NL, Gregory WA, Jackson GH, Witzens-Harig M, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Jauch A, Goldschmidt H*, Houlston RS*, Morgan GJ*, Hemminki K*. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.Nat Genet 2013;45(5):522-5.

Hemminki K, Li X, Forsti A, Sundquist J, Sundquist K. Non-Hodgkin lymphoma in familial amyloid polyneuropathy patients in Sweden. Blood, 2013; 122:458-9.

Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JA, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dörner E, Allan JM, Jauch A, Morgan GJ*, Hemminki K*, Houlston RS*, Goldschmidt H*. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet. 2013 45:1221-5 (*=equal contribution).

Frampton M, Inacio da Silva Filho M, Broderick P, Thomsen H, Försti A, Vijayakrishnan J, Cooke R, Enciso-Mora V, Hoffmann P, Nöthen MM, Lloyd A, Holroyd A, Eisele L, Jöckel KH, Ponader S, Pogge von Strandmann E, Lightfoot T, Roman E, Lake A, Montgomery D, Jarrett RF, Swerdlow AJ, Engert A, Hemminki K*,Houlston RS*. Variation at 3p24.1 and 6q23.3 influence the risk of Hodgkin’s lymphoma. Nature Commun 2013;4:2549.(*=equal contribution).

Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, Wiklund P, Steineck G, Schadendorf D, Hemminki K, Kumar R. The TERT promoter mutations in bladder cancer: effect on survival and disease recurrence and its modification by a common polymorphism. Proc Natl Acad Sci USA 2013;110:17426-31.

Weinhold N, Johnson DC, Rawstron AC, Försti A, Doughty C, Vijayakrishnan J, Broderick P, Dahir NB, Begum DB, Hosking FJ , Young K, Walker BA, Hoffmann P, Mühleisen TW, Langer C, Dörner E, Jöckel KH, Eisele L, Nöthen MM, Hose D, Davis FE, Goldschmidt*, Morgan G*, Hemminki K*, Houlston R*. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. Blood 2014;123:2513-7. (*=equal contribution).

Heidenreich B, Nagore E, P. Rachakonda S, Garcia-Casado S, Requena C, Traves V, Becker J, Soufir N, Hemminki K, Kumar R. Telomerase reverse transcriptase (TERT) promoter mutations in primary melanoma. Nature Commun 2014;5:3401.

Weinhold N, Försti A, da Silva Filho MI, Nickel J, Campo C, Hoffmann P, Nöthen MM, Hose D, Goldschmidt H, Jauch A, Langer C, Hegenbart U, Schönland SO, Hemminki K. Immunoglobulin light-chain amyloidosis shares genetic susceptibility with multiple myeloma. Leukemia. 2014 [Epub ahead of print]


nach oben